SCHEMBL20136038

SCHEMBL20136038

CC(=O)c1cc2cc(F)c(F)cc2o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.56
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 2/20 0.56
GAA P10253 2/20 0.56
HSD17B10 Q99714 2/20 0.56
GLA P06280 1/20 0.56
HPGD P15428 1/20 0.56
CASP1 P29466 1/20 0.56
BRCA1 P38398 1/20 0.56
CASP7 P55210 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
MAPT P10636 2/20 0.46
CYP3A4 P08684 1/20 0.46
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
ALOX12 P18054 1/20 0.42
KMT2A Q03164 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
FLT3 P36888 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29610111 1.00 LMNA (0.56) LMNAALDH1A1KDM4EGAAHSD17B10
SCHEMBL24139263 0.86 ALDH1A1 (0.50) LMNAALDH1A1KDM4EGAAHSD17B10
SCHEMBL24138899 0.86 ALDH1A1 (0.50) LMNAALDH1A1KDM4EGAAHSD17B10
SCHEMBL17324734 0.83 LMNA (0.50) LMNAALDH1A1KDM4EGAAHSD17B10
SCHEMBL7706250 0.82 ALDH1A1 (0.39) LMNAALDH1A1KDM4EGAAHSD17B10
SCHEMBL4310530 0.82 PIM1 (0.53) LMNAALDH1A1KDM4EHSD17B10GLA
SCHEMBL20559694 0.80 MAPT (0.45) LMNAALDH1A1KDM4EGAAHSD17B10
SCHEMBL20136031 0.78 LMNA (0.62) LMNAALDH1A1KDM4EGAAHSD17B10
SCHEMBL20135967 0.78 ALDH1A1 (0.58) LMNAALDH1A1KDM4EGAAHSD17B10
SCHEMBL1287404 0.78 LMNA (0.67) LMNAALDH1A1KDM4EGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4171563-B1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-08-06 EP disclosed
US-20250092019-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-03-20 US disclosed
EP-4228755-B1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-12-11 EP disclosed
EP-4171571-B1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-10-30 EP disclosed
US-20240352033-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-10-24 US disclosed
US-20240352032-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-10-24 US disclosed
US-11891403-B2 Tetrazole derivatives as TRPA1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-02-06 US disclosed
US-11884652-B2 Tetrazole derivatives as TRPA1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-01-30 US disclosed
EP-4228755-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS Boehringer Ingelheim International GmbH (DE) 2023-08-23 EP disclosed
US-20230257395-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-08-17 US disclosed
US-20220112210-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2022-04-14 US disclosed
US-20220002270-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-01-06 US disclosed
US-20220002270-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-01-06 US disclosed
WO-2022002782-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-01-06 WO disclosed
WO-2022002782-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-01-06 WO disclosed
WO-2022002780-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-01-06 WO disclosed
WO-2022002780-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-01-06 WO disclosed
US-20210403482-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2021-12-30 US disclosed
US-20210403482-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2021-12-30 US disclosed
EP-2828269-B1 BORONIC ACID BEARING LIPHAGANE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA AND/OR BETA COUNCIL SCIENT IND RES (IN) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092019-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS TRPA1, TRPV1, TRPV5 LMNA 3384/4885ALDH1A1 1326/4885KDM4E 4765/4885
US-11891403-B2 Tetrazole derivatives as TRPA1 inhibitors TRPA1, TRPV1, TRPV5 LMNA 3384/4885ALDH1A1 1326/4885KDM4E 4765/4885
US-11884652-B2 Tetrazole derivatives as TRPA1 inhibitors TRPA1, TRPV1, TRPV5 LMNA 3384/4885ALDH1A1 1326/4885KDM4E 4765/4885
US-20240352032-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS TRPA1, TRPV1, TRPV5 LMNA 3384/4885ALDH1A1 1326/4885KDM4E 4765/4885
US-20230257395-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS TRPA1, TRPV1, TRPV5 LMNA 3384/4885ALDH1A1 1326/4885KDM4E 4765/4885
US-20220112210-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS TRPA1, TRPV1, TRPV5 LMNA 3384/4885ALDH1A1 1326/4885KDM4E 4765/4885
US-20210403482-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS TRPA1, TRPV1, TRPV5 LMNA 3384/4885ALDH1A1 1326/4885KDM4E 4765/4885
US-20240352033-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS TRPA1, TRPV1, TRPV5 LMNA 3384/4885ALDH1A1 1326/4885KDM4E 4765/4885
US-20220002270-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS TRPA1, TRPV1, TRPV5 LMNA 3384/4885ALDH1A1 1326/4885KDM4E 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.